TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

A recently developed medication encourages people with cocaine use disorder to reduce their intake of the stimulant – a step ...

Researchers probed what psychologists call the ‘paradox of effort’ to learn how different people value work they could do in ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

Katie Medrano, program manager in the Office of Research and Sponsored Programs, noted that three performers (a band, Cade ...

The 2024 fall Research Expo has officially come to a close. Results are in, and professor Xing Wang and her team are taking ...

Dr. Kaijie He, Vice President of Innovent, stated: "With the expansion and enhancement of Innovent Academy's technology platforms, our global R&D efforts are taking shape and accelerating global ...

When two massive earthquakes (magnitudes 7.7 and 7.6) devastated southern and central Turkey in February 2023, they did more ...

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.